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 In making a credible business case for investors and industry stakeholders to 
view personalized medicine as a viable business model, we not only must create 
excitement in the promise of personalized medicine, but also must find viable 
alternatives in addressing the barriers or risks surrounding the biomedical discovery and 
development models of today. Some of the risks we identify include IP issues, 
difficulties in validating targets, ability to rapidly achieve proof of concept, navigating the 
famed “Valley of Death,” and inefficiencies in the current clinical development process, 
as well as the need for new industry business models that predict an attractive return on 
investment. In this paper; however, we limit our discussion to the potential for 
personalized medicine to create efficiencies in the preclinical and clinical phases of drug 
innovation and generate economic returns. We also introduce unique industry 
collaboration mechanisms with nonprofit disease-focused organizations that serve an 
important role in de-risking aspects of drug discovery and clinical development in their 
respective disease sectors, as well as bridging early-stage funding needs. These 
collaborations and de-risking strategies could provide an important model for the further 
development and growth of the personalized medicine sector.  
 With respect to definition, we shall use the more general term “stratified 
medicine,” of which personalized medicine is the individualized member of a spectrum 
that includes empirical medicine, stratified medicine, and personalized medicine.1 In the 
latter two, a biomarker is critical in identifying sub-populations or strata of patients that 
can benefit from a therapeutic intervention that is related to that biomarker, or develops 
                                                
1 Trusheim, Mark R., Berndt, Ernst R ., and Douglas, Frank L., “Stratified Medicine: Strategic and 
Economic Implications of Combining Drugs and Clinical Biomarkers,” NATURE REVIEWS, March 23, 2007, 
1. 
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a therapy that specifically benefits an individual who possesses that biomarker.2 A 
biomarker also may identify strata of patients that might be susceptible to side effects 
from a particular therapy.3 
 
Current Challenges in Productivity and Investment Returns    
 The increasing interest and excitement over the promise of stratified medicine is 
based on the promise of genomics, proteomics, and metabalomics to enable the 
researcher to identify genes and gene products that are relevant for disease, and to 
instruct the creation of the best therapies for patients with the respective diseases or 
side effect susceptibilities.4 This comes on the heels of the biopharmaceutical industry 
struggling to meet the increasing demands on its R&D investments while facing 
declining levels of productivity and innovation, and loss of revenue due to patent 
expirations. More than three dozen drugs are losing patent protection between 2007 
and 2012, with an anticipated $67 billion loss in sales for the large pharmaceutical 
companies to generic competition.5 The industry has responded with pharmaceutical 
companies increasing R&D spending by 160 percent—from $15 billion to $39 billion 
from 1995 to 2005—and with similar increases in the biotech industry, with a 150 
percent increase—from $8 billion to $20 billion—in R&D spending during the same 
period. Meanwhile, submissions for regulatory approval of new drugs and therapeutic 
indications declined from eighty-eight in 1995 to forty-four in 2004.6 Innovation in the 
                                                
2 Id. 
3 Id. 
4 Id. at 2. 
5 Ernst & Young, “Beyond Borders,” Global Biotechnology Report, 2008, 3. 
6 Kessel, Mark, and Frank, Frederick, “A Better Prescription for Drug-Development Financing,” Nature 
Biotechnology, 25(8):859-866, August 2007, 859-860. 
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sector also is continuing to decline, with only seventeen new molecular entities (NME) 
and two biologics approved in 2007, at a cost of $2.5 billion per NMEs approved,7 which 
is the lowest innovation-to-productivity level since 1983, when twelve NMEs were 
approved at a cost of $266 million per NME.8 (See Figure 1.)  
 
Figure 1: A comparison of biotech and pharmaceutical R&D productivity. Source: Parexel’s 
Pharmaceutical R&D Statistical Sourcebook 2005/2006; Defined Health Analysis. NME, new 
molecular entity. 
 
 The decline in productivity and innovation has increased M&A and partnering 
activities among large biopharmaceutical companies at a record high in the last few 
years, with $150 billion generated through M&A transactions in 2006 and $22 billion in 
partnering deals for the same period.9 The strategy of focusing on a few drug 
candidates from their combined pipelines, with a focus on producing several 
“blockbuster” drugs that will generate at least $1 billion individually in peak annual 
global sales and be marketable to fifteen million patients or more, has not improved 
                                                
7 McCaughan, Michael, “Another Dismal Year for New Drug Approvals.” 
8 Kessel, Mark, and Frank, Frederick, “A Better Prescription for Drug-Development Financing,” Nature 
Biotechnology, 25(8):859-866, August 2007, 859. 
9 Burrill & Company, Biotech 2007 Life Sciences: A Global Transformation, 2007, 477. 
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their productivity levels, resulting in increased delays in development time/costs and 
increasing cancellations of projects at later stages of development.10 Additionally, 
increasing regulatory pressures to conduct more lengthy and complex trials has added 
to the current $1 billion11 in drug development costs, of which half are attributable to the 
time value of money—that it takes eight to twelve years to get a drug to market.12 It is 
also the case that, even after a drug is marketed, 70 percent of the approved drugs do 
not meet or only match their R&D costs.13 Thus, with lower efficacy levels (40 percent to 
60 percent) of most blockbuster drugs,14 as well as some high-profile successes of 
stratified medicines such as Genentech’s Herceptin and Novartis’ Gleevec, the industry 
is beginning to realize the deficiencies in the economics of the blockbuster business 
model, which is one of the drivers of increased interest and investment in the 
development of stratified medicine.15 
 
A) Early-Stage Funding Challenges in Stratified Medicine Development 
 The identification of clinical biomarkers or diagnostics linked to gene expression 
profile of individual or sub-populations of patients is an essential feature of stratified or 
targeted medicine. This type of research attracts and often is best pursued by small 
biotech companies. One of the main challenges for these companies lies in the lack of 
early-stage funding to translate new discoveries into the clinic and, ultimately, to 
                                                
10 The U.S. Government Accountability Office Report: New Drug Development, Science, Business, 
Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts, GAO-07-49, 
November 2006, 30. 
11 Id. at 31; See also, Levine, Daniel S., “Getting Personal,” The Journal of Life Sciences, November 
2007, 45. 
12 PWC, Personalized Medicine, The Emerging Pharmacogenomics Revolution, February 2005, 7. 
13 Id. 
14 Id., 2. 
15 Levine, Daniel S., “Getting Personal,” The Journal of Life Sciences, November 2007, 45-46. 
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commercialization. With a narrowing access to public capital and venture capitalists 
increasingly reticent to invest in early-stage technology companies, smaller biotech 
companies increasingly are engaging in alternative financing mechanisms that often 
compromise their value in terms of access to future returns.16  
 Various alternative financing mechanisms, including partnering and out-licensing, 
sale of royalty streams, and Contract Research Organization (CRO) financings, all 
include investment capital in exchange for future royalty rights or equity shares in the 
biotech company.17 Other innovative financing mechanisms do exist, such as 
collaborative development financing (CDF), where an investor provides capital and 
clinical expertise in exchange for licensing of a company’s pipeline, while the company 
maintains the “exclusive right to reacquire the drugs,” at prices determined at the time of 
the agreement.18 An example of a CDF arrangement is the 2006 Symphony Capitol and 
Isis Pharmaceuticals (“Isis”) collaboration,19 where Isis received $75 million to continue 
the development of its cholesterol-lowering (Phase II) and diabetes drug products (two 
in pre-clinical) and agreed to an exclusive purchase option for its products at an “annual 
rate of return that averages 32 percent and is 27 percent at the end of the anticipated” 
collaboration period.20 In 2007, Isis exercised its repurchase option, paying Symphony 
$131 million. Isis, in turn, executed collaboration agreements with Johnson & Johnson 
and Genzyme for the three molecules in the contract. These arrangements included 
                                                
16 Kessel, Mark, and Frank, Frederick, “A Better Prescription for Drug-Development Financing,” Nature 
Biotechnology, 25(8):859-866, August 2007, 860. See also, NVCA News Release, July 1, 2008: For the 
first time since 1978, there were no venture-backed IPOs in the second quarter of 2008 as compared to 
forty-three IPOs in 2008. There were only five IPOs in the first quarter of 2008, compared to eighteen 
during the first quarter of 2007. NVCA News Release, July 1, 2008. 
17 Id.  
18 Id. 
19 Isis Pharmaceuticals, “Isis Pharmaceuticals and Symphony GenIsis Enter Into $75 Million Product 
Development Collaboration,” Isis Pharmaceuticals Press Release, April 7, 2006. 
20 Id. 
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upfront fees in the aggregate of $370 million with potential milestone payments of nearly 
$2 billion.21 (See Figure 2.) 
 
 
Figure 2: Alternative financing sources for biotech companies22 
 
 Most of the alternative financing mechanisms, however, are not necessarily 
accessible for many early-stage companies, as these companies may not have the 
types of products that meet the returns desired by larger companies and venture 
capitalists. A case in point is the lack of investment in orphan drugs or neglected 
disease areas. Aside from Genzyme, which has been one of the few successful orphan 
drug-focused companies with three drugs on the market, including a $1 billion-a-year 
treatment for Gaucher, and Novartis’ Gleevec, a treatment for chronic myeloid leukemia 
with $2.5 billion in 2006 sales,23 therapeutic discovery and development for orphan and 
neglected diseases often have been the bane of nonprofit foundations and patient 
advocacy organizations, many of whom have increasingly taken on a new role of 
                                                
21 Ernst & Young, “Beyond Borders,” Global Biotechnology Report, 2008, 45. 
22 Kessel, Mark, and Frank, Frederick, “A Better Prescription for Drug-Development Financing,” Nature 
Biotechnology, 25(8):859-866, August 2007, 862.   
23 Smith, Aaron, “Cashing in on Orphans,” CNNMoney.com, March 16, 2007, 1. 
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bridging early-stage funding and development gaps in disease areas where the patient 
population often is less than 200,000, the FDA definition of orphan drugs.24  
  To uncover mechanisms by which venture capitalists and biopharmaceutical 
companies—whose measures of success ultimately are captured in their return on 
investment (ROI)—could be incentivized to participate in developing stratified 
medicines, we have looked at the various activities of nonprofit foundations. In our view, 
these foundations, whose ultimate success is in bringing therapeutics and diagnostics to 
their patients, increasingly are engaged in “de-risking” strategies. In some cases, their 
target patient populations fall within the orphan disease category. Their strategies, 
however, not only fill important funding gaps but also have the objective of increasing 
the probability of success through their support activities.  
  
Venture Philanthropy—Early-Stage Funding/Proof of Concept 
 Although the nonprofit foundations traditionally provide basic research grants to 
increase scientific knowledge in their disease sectors, some have since adopted a more 
investor-like approach—early-stage funding for proof of concept and target validation, 
as well as project management support and access to their network of scientific experts 
and research clinics critical in translating discoveries into the clinic. 
 One example of nonprofit disease organizations that provide early-stage funding 
for proof of concept and target validation is the Muscular Dystrophy Association (MDA). 
Through its Translational Research Program (TRP), MDA’s approach is to stratify its 
patient population based on various sub-sets of the disease, including Duchenne 
Muscular Dystrophy (DMD), Myotonic Muscular Dystrophy (MMD/DM), 
                                                
24 http://www.fda.gov/cder/handbook/orphan.htm. 
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Fascioscapulohumeral Muscular Dystrophy (FSHD), Spinal Muscular Atrophy (SMA), 
Pompe Disease, and ALS, and seek to develop targeted therapies for the sub-patient 
populations.25 Of the $32 million in MDA’s 2007 annual R&D budget, $6 million was 
dedicated to its largest collaboration effort with ALS Therapy Development Institute 
(ALS-TDI), a nonprofit corporation, and $7 million was dedicated to industry 
collaborations.26 Muscular Dystrophy Association’s TRP provides four types of funding 
mechanisms for the industry—IND Planning Grant, Clinical Research Training Grant, 
Infrastructure Grant, and Corporate Grant—to catalyze early-stage development leading 
up to INDs and Phase I/II clinical trials.27 (See details of collaboration deal examples at 
Figure 3.)  
 
Figure 3: Examples of TRP Industry Grants28 
Disease Type & 
Company Grantees 
Collaboration Description and Status 
DMD/PTC 
Therapeutics 
MDA provided PTC with an initial $1.5 million grant, 
enabling the company to begin developing PTC124, a 
medication with the potential to treat a significant portion 
of patients with DMD. In July 2008, PTC entered into a 
collaboration deal with Genzyme, where Genzyme will 
provide $100 million to PTC, with potential additional 
payment options, and will commercialize PTC124 
outside the United States and Canada. 
 
Pompe Disease (acid 
maltase 
deficiency)/Myozyme 
(approved 2006) from 
Genzyme  
MDA provided supplemental funding of $150,000 to 
cover unreimbursed costs of patients participating in 
Genzyme’s clinical trials for Myozyme in infantile-onset 
Pompe disease. In 2007, Genzyme also found 
Myozyme effective for older children and adults with the 
disease. 
 
                                                
25 MDA 2007 Annual Report, 4-8. 
26 Interview with Sharon Hesterlee, Vice President of Translational Research, MDA, July 24, 2008. 






MDA is collaborating with ALS-TDI to comprehensively 
characterize disease progression in ALS using animal 
models of neurodegeneration and ALS clinical samples. 
MDA committed $6 million annually for three years.  
 
 To qualify for the TRP grants, the collaborating company is required to provide 
matching grants and agree to a collaboration contract that includes royalty-sharing 
agreements and march-in rights if the projects fail to meet milestone targets. Similar to a 
majority of the nonprofit disease organizations, MDA neither takes equity positions in 
the companies with which it collaborates, nor pursues IP ownership.29  
 Another example of nonprofit disease organizations providing early-stage funding 
to industry includes the Industry Discovery & Development Partnerships (IDDP) 
Program of the Juvenile Diabetes Research Foundation (JDRF). IDDP’s main focus is 
to translate scientific discoveries into the clinic and support commercialization of 
therapeutics to treat type 1 diabetes.30 Of its $160 million research budget in 2008, $16 
million will be dedicated to industry partnerships,31 which is a marked change. 
Previously, 100 percent of its research funding went to support basic science and 
exploratory research within academia.32 To date, IDDP has fostered twenty-four 
collaborations with industry, totaling $30 million in IDDP grants.33 IDDP’s development 
partnerships are generally two- to three-year contracts, and “are intended to provide 
support for promising mid-stage research programs (i.e., advancement of a pre-clinical-
stage program to clinical trials, or “proof-of-concept” Phase II clinical testing of 
                                                
29 Id. 
30 IDDP Fact Sheet, http://www.jdrf.org/files/General_Files/For_Scientists/IDDP_1_pager_10_29_07.pdf. 




promising therapeutics”34. By funding early-stage testing and validation of research, 
JDRF’s model of “de-risking” works to make it possible for its industry collaborators to 
advance their compounds from proof of concept to clinical development, attract 
additional financing, and eventually secure global licensing and marketing alliances with 
larger pharmaceutical companies.35 By funding and providing development support of 
early trials through IDDP, JDRF also sees this as a way to build evidence in persuading 
public and private payors to cover these novel technologies.36 A case in point is IDDP’s 
collaboration with Tolerx. JDRF provided early-stage, multi-million dollar funding for 
proof of concept trials in both animal models and early human trials for anti-CD3 
antibodies (Otelixizumab) for the treatment of early-stage Type 1 diabetes in 
collaboration with academic researchers in the United States and Europe.37 To catalyze 
further development and commercialization of Otelixizumab, IDDP invested $3.5 million 
in an equity stake during Tolerx’s latest round of fundraising to conduct Phase II trials.38 
This is the first project where IDDP has taken an equity position in a collaborating 
biotech company. As of October 2007, Tolerx entered into a strategic alliance deal with 
GSK to take the antibody through Phase III trials, with a total deal value potential up to 
$155 million.39 Figure 4 below also exemplifies the significant commitment IDDP has 
made to companies to support discovery, development, and commercialization of 
therapeutics and devices for type 1 diabetes. 
 




37 Interview of Peter T. Lomedico, PhD, Industry Partnerships, JDRF, September 15, 2008. 
38 Id. 
39 Interview of Peter T. Lomedico, PhD, Industry Partnerships, JDRF, July 23, 2008, and September 15, 
2008. See also, GSK/Tolerx Press Release: “GlaxoSmithKline and Tolerx Form Collaboration Worth Up 
to $155 Million,” October 23, 2007. 
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Figure 4: IDDP Discovery and Development Pipeline 
  
  
Venture Philanthropy and Nonprofit Venture Affiliates 
  Few nonprofit disease organizations have created wholly owned nonprofit 
venture affiliates to navigate through the challenges of translating early-stage 
discoveries into the clinic or bridging the “Valley of Death.” These entities serve as 
catalysts on various scales, not only by providing variable funding options from annual 
to multi-year commitments averaging from thousands to multi-millions of dollars, but 
 14 
also by providing mechanisms to address the development challenges. These include: 
providing project management expertise and scientific, clinical, and development 
networks (in some cases CRO outsourcing networks) that can assist the collaborators.  
In terms of return on investment, most do not take equity positions in the companies 
they collaborate with; instead, some deals are royalty-based, in which the organizations 
get a multiple back if the drug is approved and, in some cases, additional compensation 
for extraordinary sales results. Additionally, in cases where collaboration programs 
suspend due to milestone failures, some organizations obtain worldwide rights to 
develop the products with an agreement to negotiate royalties to the original 
collaborator once their investment is recouped. 
 An example of a nonprofit disease organization that has created unique project 
management and target validation mechanisms is the Multiple Myeloma Research 
Consortium (MMRC), a supporting organization of the Multiple Myeloma Research 
Foundation (MMRF). Through a collaborative contractual arrangement with its fifteen 
research centers,40 the MMRF’s strategy is to incentivize biopharmaceutical companies 
to collaborate on the development of new drugs and therapies. The MMRC’s tri-focus 
on genomics and credentialing of molecular targets, validation of drugs, and its offering 
of multi-site clinical trial capabilities creates efficiencies that are critical in de-risking 
early-stage proof of concept and target validation.41 One of the MMRF’s strategies is to 
                                                
40 Fifteen Consortium members include: Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center & 
Research Institute; Mayo Clinic Cancer Center; City of Hope National Medical Center; Emory University; 
Hackensack University Medical Center; Indiana University Simon Cancer Center; Ohio State University 
Comprehensive Cancer Center; Roswell Park Cancer Institute; Saint Vincent Catholic Medical Centers of 
New York; University Health Network (Princess Margaret Hospital); University of California, San 
Francisco; University of Chicago; University of Michigan, Ann Arbor; Washington University in St. Louis. 
See also, http://www.themmrc.org/model_mmrc.php.  
41 Interview with Louise Perkins, PhD, Chief Scientific Officer, Multiple Myeloma Research Foundation, 
August 13, 2008. 
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identify genetic complexities of multiple myeloma and to identify molecular targets by 
analyzing the MMRC’s tissue bank and patient data bank on disease onset and 
progression, with the goal of personalized medicine development.42 To assist in the 
process of validating new targets, the MMRC has created screening tools—including a 
panel of twelve extensively characterized myeloma cell lines with full genetic and 
biological characterization—to screen new drug candidates.43 The MMRC also has 
funded the Multiple Myeloma Genomics Initiative, investing $8 million in research 
funding over the past four years to analyze 250 patient tissue samples via gene 
expression profiling, comparative genomic hybridization and exon re-sequencing.44 To 
expedite and create efficiencies in conducting multi-site clinical trials of novel and 
combination therapies, the MMRC has created uniform contracts, clinical trial 
agreements, and correlative sciences agreements.45 (See Figure 5.) To further expedite 
the process, the MMRC provides supplemental project management to accelerate 
projects from protocol concept through trial conduct and provides clinical research 
coordinators for the MMRC members.46 The MMRF sees its main function as an 
integrator and facilitator of research and collaboration among biopharma companies 
with the research centers.47 Since 2003, the MMRF has helped bring four drugs to 
market, including Millennium Pharmaceutical’s Velcade in 2003, Celgene 
Pharmaceutical’s Thalomid® and Revlimide® in 2006, and Millennium 
                                                
42 http://www.themmrc.org/model_mmrc.php. 
43 Id. 
44 Interview with Louise Perkins, PhD, Chief Scientific Officer, Multiple Myeloma Research Foundation, 
August 13, 2008. 
45 Id. 
46 Id. 
47 Gambrill, Sara, “Venture Philanthropy on the Rise,” The CenterWatch Monthly, August 2007, 11. 
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Pharmaceutical/J&J Pharmaceutical’s Doxil® in 2007, 48 and has supported more than 
thirty compounds and combinations in trials or pre-clinical studies to date.49  
Figure 5: MMRC Clinical Trials. MMRC Trials and the year in which they have opened. A total of 15 trials 
have initiated in the MMRC since 2005. Abbreviations: R: Relapsed; R/R: Relapsed/Refractory; Rev: 
Revlimid; Dex: Dexamethasone; Vel: Velcae; IST: Investigator-sponsored trial. Unless marked as IST, all 
trials are company-sponsored. **Trials expected to open by year-end 2008.   
 
 
From a funding perspective, 93 percent of the MMRF’s annual budget goes to 
research and related programming.50 Of these, in 2007, the MMRF earmarked 
approximately $15 million for R&D, with $2 million allocated for direct funding to 
biotechs.51   
 One of the leading examples of a nonprofit venture affiliate is the Cystic Fibrosis 
Foundation Therapeutics, Inc. (CFFT), a wholly owned venture arm of the Cystic 
Fibrosis Foundation (CFF). CFFT’s focus is to develop stratified medicine based on CF-
                                                
48 Velcade in 2003,Thalomid in 2006, Revlimid in 2006, and Doxil in 2007. See also, MMRF Annual 
Report 2007, 7. 
49 Interview with Louise Perkins, PhD, Chief Scientific Officer, Multiple Myeloma Research Foundation, 
August 13, 2008. See also, http://www.themmrc.org/projects_clinicaltrials.php. 
50 Interview with Louise Perkins, PhD, Chief Scientific Officer, Multiple Myeloma Research Foundation, 
August 13, 2008. 
51 MMRF Annual Report, 2007, 5. 
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related genetic mutations, of which there are 1,400 on a single gene.52 To date, CFFT 
has successfully identified and is working on the development of therapies that target 
the basic defect of the disease, as well as those that will provide better options for 
disease management. Therapies that target the basic defect are based on various 
genetic mutations, including Delta F508, a genetic mutation present in 90 percent of 
cystic fibrosis (CF) patients, and G551D, which is present in 10 percent to 30 percent of 
CF patients.53 CFFT’s strategy is to invest in early-stage discovery and development. 
Their funding ranges from $50,000 to $25 million, with an average of $2 million to $4 
million per year, with some multi-year commitments averaging $15 million to $20 
million.54 CFFT’s successes in aiding drug discovery are measured in terms of 
increasing its pipeline, which has grown to more than thirty drug candidates.55 CFFT 
administers the collaboration contracts based on milestone successes, with pull-out 
rights for failures.56 It also invests in a wide range of technologies, from target 
identification, novel screening platforms, detection of new chemical compounds, and 
screening of existing compounds and drugs.57 In terms of return on investment, CFF 
does not take equity positions in the companies with which it collaborates; instead, 
some deals are royalty-based, in which CFF may get a multiple back and/or a percent of 
revenue if the drug is approved and, in some cases, receives additional compensation 
for extraordinary sales results.58 Should the development program suspend due to 
milestone failures, CFF obtains automatic worldwide rights to develop the product with 
                                                





57 Id.  
58 Gambrill, Sara, “Venture Philanthropy on the Rise,” The CenterWatch Monthly, August 2007, 10. 
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an agreement to provide some royalties to the original collaborator once CFF’s 
investment is recouped. 59  
 An example of CFFT’s largest industry collaboration to date includes a multi-year 
collaboration with Vertex Pharmaceuticals, Inc. (Vertex), in which CFFT provided an 
aggregate of $76 million from 2000-200860 to support the development of two 
compounds (VX-770 and VX-809), which target the functional restoration of the cystic 
fibrosis transmembrane conductance regulator (CFTR) protein, the protein responsible 
for the progression of cystic fibrosis. Through this collaboration, Vertex was able to 
develop VX-770 from discovery to Phase IIa, where it focused on how VX-770 affects 
CFTR protein function and clinical endpoints in CF patients with genotype G551D 
(affects approximately 4 percent of the 30,000 CF patient population in the United 
States), achieving positive interim results in March 2008.61 See other examples of 
CFFT’s portfolio in Table 6. 
 
Table 6: Examples of CFFT investments 
Collaborating 
Company 




Use of EPIX proprietary PREDICT 
technology to create a computerized 
3-D model of CFTR protein, using the 
model to identify sites within Delta 
F508 mutation of CFTR and search 
their library of chemical compounds 
for a small molecule that may work 
on those sites. In 2007, EPIX 
discovered a molecule that, in the 
lab, restores function to Delta F508 
CFTR in cells. 
$52 million including 
an original $18 M 
research award over 




over 7 years. 
FoldRx Use of a novel screening platform to $22 million over five 
                                                
59 Id.  
60 Interview with Robert J. Beall, PhD, President and CEO, Cystic Fibrosis Foundation, July 21, 2008. 




detect new chemical compounds that 
could improve the function of 
misfolded proteins, like the Delta 
F508 mutation. 
years to use its high-
throughput 
screening platform 
to discover and 
develop new 
compounds. 
CombinatoRx, Inc. Screening approximately 2,000 
approved drugs individually or in 
combination for its impact on 
correcting Delta F508 in the lab. 
 





Development of VX-770, its first 
CFTR modulator clinical compound, 
which entered Phase II clinical in 
2007. Also developing second 
compound known as “correctors,” 
VX-809. 
$76 million to date 
for VX-770 and  
VX-809.  
  
Venture Philanthropy and Nonprofit Venture Intermediaries  
Few large foundations, like the Gates Foundation through its Global Health 
Program (GHP), utilize independent nonprofit venture intermediaries to finance and 
manage the discovery and development of innovative therapies for neglected diseases 
affecting the developing world.62 GHP’s goal through its venture intermediaries is to 
accelerate R&D and provide global access to new vaccines, drugs, and other health 
tools that combat infectious diseases, including malaria, HIV/AIDS, TB, and 
pneumonia.63 The venture intermediaries serve “as a virtual pharma company looking 
for good ideas, progressing them to the point where proof of concept is achieved,”64 and 
de-risking projects to the point that big pharma may be incentivized to collaborate in 
developing the therapies.65 GHP is involved in the portfolio management of the venture 
                                                
62 http://www.gatesfoundation.org/nr/downloads/globalhealth/GH_fact_sheet.pdf; Interview of Tadataka 
Yamada, MD, President Global Health, Gates Foundation, August 1, 2008. 




intermediaries, but the intermediary conducts the project management.66 To date, GHP 
has committed $6 billion in global health grants to organizations and researchers 
worldwide, including $200 million to Medicine for Malaria Ventures (MMV) over five 
years.67  
The venture intermediaries, often called Product Development Public-Private 
Partnership (PDPs)68 entities, operate globally with a focus on providing R&D funding 
and project management expertise in the neglected disease areas such as Malaria and 
TB.69 MMV is one of the nonprofit venture intermediaries that the Gates Foundation and 
GHP funds.70 MMV’s role is to facilitate the discovery and development of innovative 
anti-malarial drug candidates into clinic.71 MMV does not conduct discovery or 
development itself but provides financial and project management support requiring 
milestone achievements and quick termination rights for those who fail to meet 
milestones.72 In return for its investments, MMV often seeks IP rights from the discovery 
and development projects it funds.73 In projects that it funds through commercialization, 
MMV will often negotiate for the delivery of drugs to poor developing countries at "no 
profit, no loss" basis.74 It also will retain the ability to license to multiple drug 
                                                
66 Id. 
67 Id. 
68 PDPs are defined as arrangements that innovatively combine different skills and resources from 
institutions in the public and private sectors to address persistent global health problems. Global Forum 
for Health Research, Helping Correct the 10/90 Gap, 2008 report at 11. 
69 Id. 
70 Since 1999, MMV has received $318 million in funds and pledges from private foundations, 
governments, international organizations, and industry. More than 63 percent ($200 million) of its pledged 
funding comes from the Gates Foundation’s Global Health Program, and 27 percent ($86 million) comes 
from five foreign government agencies and two UN organizations (World Bank and WHO). MMV Annual 
Report 2007, 46. 
71 MMV at a Glance, MMV: Past, Present, and Future, 2. 
72 Id. 
73 MMV IP Position Paper, http://www.mmv.org/article.php3?ID_article=290. 
74 Id. 
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manufacturers.75 In cases where industry partnership fails during the development 
phase, MMV will either take full ownership of the IP or require an exclusive, worldwide, 
transferable license that is royalty free in malaria endemic countries.76   
  In 2007, MMV invested more than $37 million in nearly forty projects that include 
four projects in late-stage Phase III clinical trials and three mini-portfolios with 
GlaxoSmithKline (GSK) (three projects), the Broad Foundation/Genzyme (five projects), 
and Novartis Institute for Tropical Diseases (NITD)/Novartis (nine projects).77 Clinical 
trials MMA supported in 2007 include: Collaboration with Novartis' submission to 
Swissmedic for approval of its first ACT (Coartem® Dispersible); Eurartesim® (with 
Sigma-Tau Pharmaceuticals, Inc.), which received orphan drug designation in the U.S. 
in 2006 and by the EU in 2008; and MMV/Shin-Poong Pharmaceuticals collaboration for 
Pyramax®. MMV has a wide platform in its collaboration with Shin-Poong, covering two 
pivotal trials for Plasmodium falciparum, trials for P. vivax, and also a new formulation 
specifically for small children.78    
MMV also has engaged in identifying new targets based on the genome 
sequence of Plasmodium falciparum, the main cause of human malaria, and has 
collaborated with Novartis and GSK to screen their collection of compounds that may be 
able to kill the malaria parasite. Out of more than three million compounds tested, more 
than 10,000 showed interesting activities at low micromolar concentrations.79 (See 
Figure 7.) 
                                                
75 MMV IP Position Paper, http://www.mmv.org/article.php3?ID_article=290. 
76 MMV Annual Report 2007, 18-25. 
77 Id. 
78 Id., 85-25. 
79 Id., 16. 
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Figure 7: Sample MMV investments in 200780 
Collaborating 
Company 






Phase III trial—Development of a 
pediatric dispersible tablet, Coartem® 
Dispersible, containing a fixed-dose 








Phase III trial—Fixed-ratio drug 
combination of dihydroartemisinin and 







Phase III trial—Fixed-dose oral 
combination of artesunate with 
pyronaridine. The course of treatment is 
once a day for three days. Currently 
carrying out pivotal Phase III studies in 
Plasmodium falciparum and P. vivax 
patients to confirm safety and efficacy. 
A specific pediatric granule formulation 







Engaged in five separate projects 
ranging from 1) development of next-
generation pyridones derivative; 2) 
development of a second-generation 
macrolide; 3) identification of additional 
potent falcipains inhibitors; 4) high-
throughput screening assay to study the 
effect of the entire GSK library of 
compounds on the growth and death of 
P. falciparum (To date, the majority of 
the 1.5 million compounds have been 
screened in a high-throughput assay, 
and more than 10,000 hits have so far 
been identified with interesting activity. 
The goal for 2008 is to complete the 
screen, characterize the hits, and use 
chemo-informatic technologies to 
cluster them.); and 5) discovery 
US $2.2 million  
                                                
80 Id., 18-20. 
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program to screen new class of 
compounds, namely THiQ, that showed 
promising activity against P. falciparum 
from its previous Fab1 project. 
 
MMV/Broad Institute 




Engaged in three projects: 1) screening 
of the broad compound collection 
against whole parasite assays with 
expansion plans in 2008 to include 
more compounds from the Genzyme 
library; 2) identification of natural 
products for malaria treatment; and 3) 
use of proteomics technology to identify 
molecular targets. Targets for one of the 
natural products have been identified, 
allowing it to be developed for a 
molecular-based, high-throughput 
screening (HTS) assay. Focus is to 
continue identifying more molecular 
targets that will not only be essential for 
parasite growth, but tractable in terms of 






Engaged in nine projects ranging from 
early-stage research into identifying 
new targets for liver stages of P. vivax 
infection, through to optimization of 
compounds based on artemisinin 
dimmers. Several projects are moving 
forward from early-stage hits to lead 
compounds. One is the chemistry 
strategy based on successful screening 
of more than two million compounds 
from the Novartis compound collection, 
which led to the selection of more than 




 As demonstrated above, the nonprofit disease organizations are having an 
impact on translating early-stage discoveries to development phases, not only by 
providing funding for proof of concept and target validation but also by providing project 
management and a ready-made network of scientific and clinical infrastructures to 
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expedite and de-risk the development of novel therapies. These approaches are 
instructive for developing and funding early-stage development models for the stratified 
medicine sector, but are only part of the picture in making a business case for stratified 
medicine. We also must assess the clinical trial development risks and how the 
nonprofit disease organizations may contribute in de-risking clinical development and its 
applicability to stratified medicine, which will be discussed in the next segment of this 
paper. 
 
B) Risks and Impact on Return: De-risking Clinical Trials 
  The critical part of assessing potential return on biomedical product development 
hinges on the assessment of risk factors in terms of clinical development costs, time, 
and success probabilities to get to market.81 Although most venture capitalists and 
biopharmaceutical companies use their own valuation models to assess potential 
investment returns of biomedical products in development, a baseline industry average 
provides a snapshot of the development risk factors and possible mitigation strategies 
to employ through unique collaborative models with nonprofit disease organizations.82  
 
Development Risk and Clinical Trial Design  
 With increasingly complex and chronic diseases as potential targets for new 
biomedical innovations, the industry is continuing to face decreasing productivity and 
increasing clinical trial failure rates, adding to the increase in development risks in terms 
                                                
81 Kiev, Ari, “Risks, Reward, and Valuation in Clinical Stage Development: Challenge Your Perspective,” 
Presentation at Investment and Clinical Challenges in the Biotech Industry Conference, Munich, 
Germany, April 7, 2008. 
82 Ustunel, Sarpel, “How to Put an Accurate Value on Biotech Firms,” Professional Investor, October 
2005, 20. 
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of cost/time.83 Currently, approximately 80 percent of Phase I trials are expected to fail 
(i.e., they have a 20 percent chance of successfully making it to market), and 70 percent 
are expected to fail in Phase II,84 with expected success rates from Phase III to market 
between 50 percent and 70 percent. New biologic molecular entities have slightly better 
success rates than those identified for new chemical entities.85  
 These tools will play a significant role in de-risking the drug development 
process.86 Continued advancement in new genomics-based technologies and high 
throughput screening tools will improve researchers’ abilities to discover reliable clinical 
biomarkers that can stratify and enable the discovery of the best therapies for patients.87  
For instance, use of clinical biomarkers early in the clinical trial process could help to 
decrease costs by identifying better responders, thereby reducing trial sample size to 
demonstrate efficacy and help to exclude patients early using toxicity biomarkers.88 In 
addition, stratifying for key biomarkers early in the trial process not only creates the 
possibility of shortening end-point observation times, but also creates the ability to 
gather data to improve the compound or alter the trial design altogether early on, 
allowing for educated data mining to better define the appropriate patient population.89 
                                                
83 The U.S. Government Accountability Office Report: New Drug Development, Science, Business, 
Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts, GAO-07-49, 
November 2006, 25. 
84 Stewart, Jeffrey J., “Biotechnology Valuations for the 21st Century,” Milken Institute Policy Brief, April 
2002, 6. 
85 Ustunel, Sarpel, “How to Put an Accurate Value on Biotech Firms,” Professional Investor, October 
2005, 20. 
86 Trusheim, Mark R., Berndt, Ernst R., and Douglas, Frank L., “Stratified Medicine: Strategic and 
Economic Implications of Combining Drugs and Clinical Biomarkers,” NATURE REVIEWS, March 23, 2007, 
3. See also, PriceWaterhouseCoopers LLP, “Personalized Medicine: The Emerging Pharmacogenomics 
Revolution,” Global Technology Centre, Health Research Institute, February 2005, 12-13. 
87 The U.S. Government Accountability Office Report: New Drug Development, Science, Business, 
Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts, GAO-07-49, 




Additionally, the collection of DNA information from ongoing clinical studies, with 
patients’ consent, also offers the possibility to accelerate future research with increased 
efficiency.90 Shorter trials with specific results also have the advantage of expedited 
FDA reviews, as exemplified by FDA’s review and approval of Genentech/Roche’s 
breast cancer treatment, Herceptin, which took six months,91 or that of Novartis’ 
Gleevec, which took three months. It is anticipated that stratifying patients based on 
clinical biomarkers may reduce the cost of clinical trials by a factor of two to five, as it 
would help to narrow the test populations and commercialization time from the current 
ten to twelve years to five years or less.92  
 
Time/Cost Correlation 
 The current industry expectations are the following—in Phase I of the clinical trials, 
twenty to eighty healthy volunteers are given a new drug compound to test for safety at a 
cost ranging from $8,000 to $15,000 per patient with an average time period of six months 
to a year.93 In Phase II, 100 to 300 patients are given the new drug compound to assess 
clinical efficacy and dosage levels at a cost ranging from $8,000 to $15,000 per patient, 
with an average time period of two to three years.94 In Phase III, 1,000 to 5,000 patients 
are tested, often in placebo-controlled, randomized, and double-blinded trials for efficacy 
and overall risk-benefit assessment at a cost of $4,000 to $7,500 per patient. These data 
                                                
90 PriceWaterhouseCoopers LLP, “Personalized Medicine: The Emerging Pharmacogenomics 
Revolution,” Global Technology Centre, Health Research Institute, February 2005, 13. 
91 Id. Note: Herceptin is a unique example in that it also relied on a diagnostic test that clearly identified 
which subset of breast cancer patients would be expected to achieve better results and serious side 
effects from Herceptin. 
92 PriceWaterhouseCoopers LLP, “Personalized Medicine: The Emerging Pharmacogenomics 
Revolution,” Global Technology Centre, Health Research Institute, February 2005, 14. 
93 Id. See also, Jeffrey J. Stewart, “Biotechnology Valuations for the 21st Century,” Milken Institute, April 
2002, 7.  
94 Id. 
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sets, however, do not provide a clear picture of the real drivers of time/cost correlation. 
For instance, key drivers of time delay in clinical trials include difficulties in patient 
recruitment (this causes 33 percent to 66 percent of time delay) and data management  
(8 percent to 14 percent), as well as difficulty in manufacturing and regulatory/ethics 
approvals,95 resulting in upwards of 75 percent of all U.S. trials experiencing delays of one 
to six months or more.96 With more than 40 percent to 50 percent of per-patient costs 
attributable to clinical operations, including project management, monitoring, and 
regulatory and data management,97 finding ways to mitigate delays and deploying 
strategies to increase efficiencies in the clinical process will be critical in decreasing risks 
associated with development costs/time. (See Figure 8.)  
                                                
95 Kiev, Ari, “Risks, Reward, and Valuation in Clinical Stage Development: Challenge Your Perspective,” 
Presentation at Investment and Clinical Challenges in the Biotech Industry Conference, Munich, 




Figure 8: Clinical Trial Parameters98  
 
 
Venture Philanthropy—Clinical Trial De-risking Mechanisms 
 In identifying ways to de-risk the time/cost factors in clinical development, one of 
the emerging models is industry collaboration with nonprofit foundations which, at 
varying levels, offer mechanisms to expedite and create efficiencies such as readily 
accessible patient registries and databases, and a broad network of clinical and 
investigator sites that offer scientific expertise and support.  
 
                                                
98 Stewart, Jeffrey J., “Biotechnology Valuations for the 21st Century,” Milken Institute Policy Brief, April 
2002, 7. 
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Venture Philanthropy and Patient Registry/Database 
 Patient recruitment in clinical trials, especially for specific disease indications, are 
extremely time consuming and often difficult, adding tremendously to clinical trial 
time/costs. One of the important de-risking mechanisms provided by the nonprofit 
disease organizations is access to their network of patient registries and databases. 
Although most organizations are at various stages of developing their patient registries, 
Cystic Fibrosis Foundation (CFF) has created an extensive infrastructure to serve this 
purpose. For instance, CFF accredits more than 115 cystic fibrosis care centers with 
ninety-five adult care programs and fifty affiliate programs nationwide,99 creating one of 
the largest patient registry databases among U.S. foundations, with information about 
more than 24,000 CF patients receiving care at one of the CF care centers.100 CFF’s 
database includes not only the patient contact information, but detailed information 
about genotypes, pulmonary function test (PFT) results, pancreatic enzyme uses, length 
of hospitalizations, home IV use and complications related to CF, which are critical in 
assessing trends and in clinical trial designs.101 The MMRC also has developed a 
patient database consisting of contact information from 165,000 patients and has 
launched a new initiative called the patient navigator program to identify and match 
patients with clinical trials.102  
 




102 Interview with Louise Perkins, PhD, Director of Research, Multiple Myeloma Research Foundation, 
August 13, 2008. 
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Venture Philanthropy and Clinical Trial Networks  
 One of the critical de-risking mechanisms in terms of development time/costs that 
many of the nonprofit disease organizations offer is their extensive network of clinical 
trial sites and expert investigators, as well as information about the ongoing trials in their 
networks. This offers the ability to conduct multi-site trials with expediency, combined 
knowledge, and access to quality data from the ongoing trials. Such clinical trial 
networks also provide the ability to scale up quickly in Phase III studies and, in some 
cases, conduct Phase IV studies.103 An important aspect about such a network is the 
nonprofit disease organizations’ collaborative approach to trials, as they often offer 
centralized review of clinical trial protocols, are able to set common policies to protect 
patient safety, establish standardized research procedures, share expertise among top 
researchers, and provide network-wide staff training.104  
 CFF may be one of the leading organizations that, through its Therapeutics 
Development Network (TDN), offers access to its network of eighteen clinical research 
centers that specialize in conducting Phase I and II studies for treatment of CF.105 TDN 
centralizes and standardizes CF research while providing access to clinical trials data 
and CF experts through a centralized coordinating center at the Children’s Hospital in 
Seattle, Washington.106 To enlarge its network, CFF invested $3 million in 2007 in forty-
five new research centers in twenty states nationwide to build an infrastructure to help 
with patient recruitment and to increase its clinical network.107 As discussed previously, 
                                                




107 Interview with Robert J. Beall, PhD, President and CEO, Cystic Fibrosis Foundation, July 21, 2008. 
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the MMRF also offers a network of fifteen academic centers that collaborate in 
conducting multi-site clinical trials.108  
 To increase efficiencies, productivity, and sustainability of conducting clinical 
trials in developing countries, MMV works with a network of international organizations 
such as the Malaria Clinical Trials Alliance (MCTA), Malaria Vaccine Initiative (MVI), 
and the INDEPTH Network.109 MCTA facilitates site preparation for effective conduct of 
Good Clinical Practices-compliant trials for malaria vaccines and therapies, while 
supporting the long-term development and sustainability of clinical trial sites in nine 
countries across Africa (Mozambique, Tanzania, Malawi, Gabon, Nigeria, Ghana, The 
Gambia, Kenya, and Senegal).110 MVV also works with the European & Developing 
Countries Clinical Trials Partnership (EDCTP) to facilitate Phase II and III clinical trials 
in HIV/AIDS, malaria, and tuberculosis in sub-Saharan Africa.111  
 
Assessment and Recommendation 
 To reverse the trend of declining productivity and innovation, and embrace the 
new technological and scientific advances that will allow for safer and more effective 
treatment of diseases through stratified medicine, industry stakeholders must be open 
to unique models that could de-risk current drug development processes and increase 
their combined probabilities of success. Through our discussion, we have identified new 
collaborative mechanisms with nonprofit disease organizations that can not only help 
                                                
108See also, http://www.themmrc.org/model_mmrc.php.  
109 http://www.indepth-network.net/mcta/mctaindex.htm. 
110 Id.; MCTA was created in 2006 through a $17 million grant from the Gates Foundation.  
111 EDCTP was created in 2003 as an international organization funded and governed by the fourteen EU 
Member states, plus Norway and Switzerland, with forty-seven sub-Saharan African countries. See also, 
http://www.edctp.org/Fequently_Asked_Questions_FAQ.435.0.html. 
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bridge some of the funding gaps in early-stage discovery and development of new 
technologies, but more importantly, de-risk the clinical process in terms of time and 
costs.  












Cystic Fibrosis          
Multiple 
Myeloma 
          
Myelin Repair        
Juvenile 
Diabetes 
        
 
In the short term, these mechanisms offer a model for the biopharmaceutical industry in 
how they can better work with existing nonprofit organizations to capitalize on their 
offerings. The elements of such a model would include biopharmaceutical companies 
collaborating with other groups, such as nonprofit foundations, who could establish and 
manage the programmatic research of networks of academic and investigators from 
small biotechnology companies, patient registries, and expert clinical centers. In return, 
large biopharmaceutical companies would provide some funding and commitment to 
take over the late-stage development of “de-risked” clinical candidates to approval and 
marketing. There could be several innovative ways to reward the nonprofits for their 
contribution without violating their mission or 501(c)(3) status.  
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A critical success factor in stratified medicine is the discovery of the biomarker and/or 
diagnostic kit. Intellectual property rights can be a potential barrier when there is only 
one supplier of the diagnostic kit, particularly if that kit has not been approved by 
regulatory bodies. This presents challenges in reimbursement, as well as potential 
liability issues if such a kit is used to qualify patients for a drug, and the specificity and 
sensitivity of the diagnostic test have not been established. This liability exists for both 
tests of efficacy and susceptibility to side effects. There is, therefore, need to address 
this downstream issue of potential biomarkers that are discovered in the NIH and other 
Biomarker consortia. 
In summary, this paper focuses on ways to address two of the issues—return on 
investment and probability of success—that are barriers to the adoption of stratified 
medicine by large biopharmaceutical companies. The various activities of some 
foundations serve to identify the relevant patient subgroups and generate data to better 
qualify potential drug candidates. We call these “de-risking” activities, which not only fill 
gaps in funding, but improve the probability of success of the drug discovery and 
development effort. These diseases also are excellent examples where subgroups of 
patients might be discovered and stratified, and prospective health care—anticipation, 
prevention, intervention—as described by Dr. Ralph Snyderman, could be pursued on a 
more rational basis. Thus collaboration between large biopharmaceutical companies 
and disease foundations provides an interesting model within which several aspects of 
the development and implementation of prospective health care and stratified medicine 
might be assessed for technological and economic feasibility. 
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However, a broader challenge remains in the ability to scale these de-risking 
mechanisms to a larger set of disease sectors, and on the question of who will bear the 
cost of creating the necessary infrastructures. One possibility is the U.S. government; 
as such efforts would be consistent with both the FDA’s Critical Path Initiative and the 
NIH Road Map. We would argue that both the FDA and NIH, under these two initiatives, 
could encourage the collaborative model suggested in this paper, either by disease 
category, such as cancer, where there is a known familial or genetic predisposition for 
the disease. In addition, two areas need to be urgently evaluated or assessed: the 
barriers that present intellectual property rights pose to adoption of the collaborative 
model, and the financial value of the varying de-risking strategies that we have 
discussed. These are the questions we pose today in opening the discussion on how 
we can make a business case for the growth and adoption of stratified or personalized 
medicine in the near future. 
 
